Clinical Trial Detail

NCT ID NCT03974217
Title Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Talazoparib

Age Groups: adult senior

Additional content available in CKB BOOST